Fmr LLC Vanda Pharmaceuticals Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Fmr LLC holds 118,937 shares of VNDA stock, worth $597,063. This represents 0.0% of its overall portfolio holdings.

Number of Shares

118,937

Previous 112,243 5.96%

Holding current value

$597,063

Previous $461,000 45.55%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.91 - $6.5 $26,173 - $43,511	6,694 Added 5.96%	118,937 $671,000
Q1 2024 May 13, 2024	SELL	$3.47 - $4.61 $5,739 - $7,624	-1,654 Reduced 1.45%	112,243 $461,000
Q4 2023 Feb 13, 2024	SELL	$3.38 - $4.58 $23,105 - $31,308	-6,836 Reduced 5.66%	113,897 $480,000
Q3 2023 Nov 13, 2023	BUY	$4.28 - $6.57 $174,362 - $267,655	40,739 Added 50.93%	120,733 $521,000
Q2 2023 Aug 11, 2023	BUY	$5.9 - $6.95 $2,778 - $3,273	471 Added 0.59%	79,994 $527,000
Q1 2023 May 11, 2023	BUY	$6.18 - $7.99 $30,708 - $39,702	4,969 Added 6.66%	79,523 $539,000
Q4 2022 Feb 13, 2023	BUY	$6.87 - $10.96 $126,442 - $201,718	18,405 Added 32.78%	74,554 $550,000
Q3 2022 Nov 10, 2022	BUY	$9.44 - $11.76 $22,268 - $27,741	2,359 Added 4.39%	56,149 $555,000
Q2 2022 Aug 12, 2022	SELL	$9.31 - $11.84 $2,057 - $2,616	-221 Reduced 0.41%	53,790 $586,000
Q1 2022 May 13, 2022	BUY	$10.84 - $16.55 $573,880 - $876,173	52,941 Added 4947.76%	54,011 $611,000
Q4 2021 Feb 14, 2022	SELL	$15.69 - $21.14 $125 - $169	-8 Reduced 0.74%	1,070 $17,000
Q2 2021 Aug 13, 2021	BUY	$15.71 - $21.51 $16,935 - $23,187	1,078 New	1,078 $23,000

Others Institutions Holding VNDA

# of Institutions

153

Shares Held

44.9M

Call Options Held

132K

Put Options Held

220K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $284M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account